Abiopharma

🔍 McMahon Stephen A (Executive)

Company: Dynatrace, Inc. (DT)

Report Date: 2026-06-05

Detailed Transactions and Holdings:

• Acquired 23,285 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 27,240.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 12,560 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 14,680.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 15,926 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 30,606.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 8,593 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 22,013.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 23,285 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 69,853.00 | transaction_form_type: 4 | Footnotes: F1, F4, F1
• Sold 15,926 shares of Performance Restricted Stock Units (Financial) (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 47,776.00 | transaction_form_type: 4 | Footnotes: F1, F5, F1
• Acquired 37,924 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 37,924.00 | transaction_form_type: 4 | Footnotes: F1, F6, F1

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units do not expire. They either vest or are cancelled prior to the vesting date.
• F2: Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations upon the vesting of restricted stock units.
• F3: The number of securities reported reflects the acquisition on June 5, 2026 of 501 shares of Common Stock pursuant to the Issuer's Employee Stock Purchase Plan ("ESPP") for the ESPP offering period of December 6, 2025 through June 5, 2026.
• F4: Represents the vesting of time-based restricted stock units ("RSUs") granted on June 5, 2025 under the Issuer's 2019 Equity Incentive Plan, as amended (the "Plan"). 25% of these RSUs vested on June 5, 2026 and the balance of the RSUs vest in equal quarterly installments thereafter until fully vested on June 5, 2029, subject to the Reporting Person's continued employment on the applicable vesting dates.
• F5: Represents the vesting of Financial PSUs granted on June 5, 2025 under the Plan and earned following certification by the Compensation Committee of the Board of Directors of the Issuer of certain financial performance results for the Issuer's fiscal year 2026 that started on April 1, 2025 and ended on March 31, 2026. 33% of the Financial PSUs vested on June 5, 2026, and the balance of the Financial PSUs vest in equal quarterly installments thereafter until fully vested on June 5, 2028, subject to the Reporting Person's continued employment on the applicable vesting dates.
• F6: Represents the grant of RSUs under the Plan. 33% of these RSUs will vest on June 5, 2027 and the balance of the RSUs will vest in equal quarterly installments thereafter until fully vested on June 5, 2029, subject to the Reporting Person's continued employment on the applicable vesting dates.